Danaher earnings increased in the third quarter of 2026 as revenue reached $6.6 billion, and the life sciences and diagnostics company raised its full-year adjusted earnings forecast. The October 21 announcement also projected continued underlying growth in the fourth quarter, although respiratory revenue is expected to weigh on the total.
Key Takeaways
- Third-quarter revenue rose 8.5%, while adjusted diluted earnings per share increased 11.5% to $2.11.
- Core revenue grew 5.5% excluding respiratory revenue, compared with 3.0% when respiratory revenue was included.
- Danaher raised its 2026 adjusted earnings guidance and forecast fourth-quarter core growth of approximately 3.0%.
Table of Contents
- Danaher earnings show growth beyond respiratory revenue
- Fourth-quarter outlook separates underlying demand from respiratory pressure
- Higher annual profit range accompanies growth priorities
- Conclusion
Danaher earnings show growth beyond respiratory revenue
Danaher’s third-quarter results announcement covered the three months ended September 25, 2026. The company reported diluted earnings from continuing operations of $1.71 per share, compared with $1.27 a year earlier. Adjusted diluted earnings, a non-GAAP measure, rose to $2.11 from $1.89.
Revenue growth differed depending on the measure used. Reported sales increased 8.5%, while non-GAAP core revenue grew 3.0%. Excluding respiratory revenue, core growth was 5.5%, showing that respiratory revenue held back the broader core growth rate.
Chief Executive Julie Sawyer Montgomery said revenue, earnings and cash flow were better than management had expected. She also pointed to improving trends across Danaher’s end markets and credited execution through the Danaher Business System with helping convert demand into financial performance.
| Item | Details |
|---|---|
| Q3 2026 operating cash flow | $1.9 billion |
| Q3 2026 non-GAAP free cash flow | $1.6 billion |
| Previous 2026 adjusted diluted EPS guidance | $8.45–$8.60 |
| Revised 2026 adjusted diluted EPS guidance | $8.57–$8.62 |
Fourth-quarter outlook separates underlying demand from respiratory pressure
For the fourth quarter of 2026, Danaher expects non-GAAP core revenue growth excluding respiratory revenue of 4.0%–5.0% year over year. Respiratory revenue is expected to create an approximately 150-basis-point headwind, leaving total core revenue growth at approximately 3.0%.
That distinction matters when comparing the outlook with the latest results: the 4.0%–5.0% forecast excludes respiratory revenue and should not be treated as guidance for total core growth.
Chief Financial Officer Matthew Gugino also projected an adjusted operating profit margin near 29.5%. These figures are management forecasts, not completed results.
Higher annual profit range accompanies growth priorities
Danaher increased both ends of its full-year adjusted diluted earnings-per-share guidance. The revised range follows a quarter that also generated substantial operating and free cash flow.
Sawyer Montgomery framed the company’s priorities around gaining market share and delivering sustainable profitable growth in life sciences and diagnostics. Those statements describe management’s ambitions rather than confirmed future outcomes.
Danaher said it could not reconcile its forward-looking non-GAAP measures fully to comparable GAAP measures because several potentially material items depend on uncertain future events.
Conclusion
The next performance checkpoint is the fourth quarter: whether Danaher delivers its projected core growth despite respiratory pressure and finishes 2026 within its higher adjusted earnings range.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
